Standout Papers

Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis 2024 202694
  1. Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis (2025)
    Danny Issa, Philip N. Newsome et al. New England Journal of Medicine
  2. Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial (2024)
    Philip N. Newsome, Arun J. Sanyal et al. Alimentary Pharmacology & Therapeutics

Immediate Impact

10 standout
Sub-graph 1 of 5

Citing Papers

Metabolic dysfunction-associated steatotic liver disease in adults
2025 Standout
From Cardiovascular-Kidney-Metabolic Syndrome to Cardiovascular-Renal-Hepatic-Metabolic Syndrome: Proposing an Expanded Framework
2025 Standout
1 intermediate paper

Works of Mary E. Rinella being referenced

Semaglutide 2.4 mg in Participants With Metabolic Dysfunction‐Associated Steatohepatitis: Baseline Characteristics and Design of the Phase 3 ESSENCE Trial
2024 Standout

Author Peers

Author Last Decade Papers Cites
Mary E. Rinella 99 90 30 36 9 154
Michail Kokkorakis 77 68 57 26 13 187
Arun J. Sanyal 125 117 46 49 7 239
Samina Ajaz Hussain 130 142 51 47 8 217
Kazuhide Ishikura 92 86 25 32 12 199
Rie Ibusuki 106 48 30 26 13 193
Nicole Aumann 72 110 25 39 7 225
Yuliya Kupriyanova 118 79 89 24 17 204
Esteban González Ballerga 83 46 29 24 16 142
J. Ockenga 55 31 52 50 10 148
Youwen Yuan 95 37 33 22 12 182

All Works

Loading papers...

Rankless by CCL
2026